Phase 1 Alzheimer Disease, Early Onset Clinical Trials

4 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 1–4 of 4 trials

Recruiting

Phase 1Phase 2

Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease

Alzheimer DiseaseAlzheimer Disease, Early Onset

Arrowhead Pharmaceuticals112 enrolled1 locationNCT07221344

Recruiting

Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease

Alzheimer Disease, Early Onset

Denali Therapeutics Inc.68 enrolled1 locationNCT07328451

Recruiting

Phase 1

A Study to Assess THN391 in Subjects With Alzheimer's Disease

Alzheimer Disease, Early Onset

Therini Bio, Inc.15 enrolled4 locationsNCT06814730

Recruiting

Phase 1

Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD

Alzheimer Disease, Early OnsetMild Cognitive ImpairmentModerate Dementia

Butler Hospital35 enrolled2 locationsNCT04500847